Organicell Appoints Harry Leider, MD, MBA as New CEO

Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a South Florida-based clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce that it has tapped Harry L. Leider, MD, MBA as its new CEO.

Dr. Harry Leider brings more than 25 years of experience as a healthcare executive and entrepreneur, with extensive experience serving in C-suite roles in both publicly-held and early-stage companies, to the position. He has advanced breakthroughs in patient care across multiple sectors of the health care industry.

Prior to joining Organicell, Dr. Leider served as the chief medical officer and executive vice president of Gelesis, a biotech company specializing in therapies for obesity. Under his leadership, the company successfully completed the process to gain FDA approval for its lead product, Plenity®; and then successfully commercialized Plenity via a unique direct-to-consumer model supported by a national telemedicine program. Furthermore, he played a key role as part of a small leadership team that led the company through its initial public offering on the New York Stock Exchange (NYSE).

Before that time, Dr. Leider served as chief medical officer and group vice president for Walgreens Boots Alliance, a Fortune 50 company where he provided leadership for all clinical programs, quality assessment activities, health outcomes research, and health analytics projects. Prior to Walgreens, he served as chief medical officer and executive vice president at Ameritox, a specialty laboratory company that enabled physicians to more safely treat patients suffering with chronic pain. He has also participated on the Board of Directors of Alivio Therapeutics, TytoCare, and Mobile Help.

During his career, Dr. Leider has served on the faculty of the Johns Hopkins Carey School of Business and Harvard Medical School, and has published more than 25 articles and chapters related to patient care and organizational leadership in peer-reviewed journals and books. He also was a core faculty member of the American Association of Physician Leadership for more than 20 years and has published five patents in the field of laboratory medicine.

“Harry brings an extensive track record of successfully launching innovative therapeutics and services that have positively impacted the practice of medicine. I am honored and excited to welcome him to our seasoned leadership team,” said Ian Bothwell, chief financial officer of Organicell. “Harry’s research and commercial expertise, along with his broad strategic business perspective, will enable Organicell to rapidly advance its successful research and commercial programs while transforming the regenerative medicine space.”

Dr. Leider stated, “I am honored to lead Organicell and work alongside a highly talented team of executives, researchers, and business associates. Together, we have a truly unique opportunity to develop and commercialize an entirely new class of therapies for important clinical conditions, while building a word-class biotherapeutic company.”

Other Executives In the News

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

Dr. Val Kolesnitchenko brings extensive ophthalmology experience in clinical practice and industry to new therapeutics for the aging eye.
These strategic appointments signify a significant milestone for BRIJ Medical as they usher in a new era of post-surgical and trauma incision care with proven technologies that minimize wound complications and scarring.
Dr. Eckhard von Keutz has extensive experience in designing and conducting preclinical/toxicological studies, and toxicological risk assessment and management.
David Kroekel has more than 35 years of experience in medical device, combination product operations, and product development.
Dr. Konstantin Kousoulas, a leading virologist will work to further Rational Vaccines core mission of eradicating the world of the herpes simplex virus. "Dr. Kousoulas...

By using this website you agree to accept Medical Device News Magazine Privacy Policy